Improving the bioavailability of nintedanib by formulating inhalable ufasomes as a targeted therapy for non-small cell lung cancer

The safety and effectiveness of nintedanib in treating non-small cell lung cancer (NSCLC) have been evaluated in several clinical trials. However, nintedanib exhibits low oral bioavailability due to its poor solubility and first-pass metabolism. To enhance the sustainability, targeting, bioavailabil...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Salman M. Ghazwani, Sami Alhazmi, Salhah M. Ghazwani, Hussam M. Shubaily, Ahmed M. Wafi, Naifa Alenazi, Marwa Qadri, Amal Naif Alshammari, Wedad Mawkili, Jobran M. Moshi, Zenat Khired, Salama A. Salama
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Elsevier 2026-06-01
Saila:	International Journal of Pharmaceutics: X
Gaiak:	Lung cancer Lewis lung carcinoma Targeting Nintedanib Bioavailability
Sarrera elektronikoa:	http://www.sciencedirect.com/science/article/pii/S2590156725001677
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!